I find it very interesting that we haven’t had any data from the...

I find it very interesting that we haven’t had any data from the combination arm of Vaxinia MAST trial. Pembrolizumab is an immunotherapy that stimulates the immune system and should work well in combination with CF33. Marketed as Keytruda and coming off patent in 3-4 years, its annual sales are up around US$28 billion.

I understand the primary endpoint for MAST is safety so perhaps that’s why we haven’t heard from this arm of the trial given the known safety/toxicity issues of Keytruda. Still, I’m keen to see how it stacks up against the mono therapy arm. i guess we will get this data closer to the discovery of OBD and the end of the trial sometime in 2025. So much to look forward to next year.